combined tumor vaccines with PD-1/CTLA-4 blockage to successfully improve the activity of effector T cells in mouse tumor cells, weaken the inhibitory effect of T-reg and strengthen the therapeutic effect of PD-1/CTLA-4 blockage. The gene discussed is CTLA4; the disease is neoplasm.